{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361981470165781376.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1046/j.0306-5251.2001.01476.x"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.0306-5251.2001.01476.x"}},{"identifier":{"@type":"URI","@value":"https://bpspubs.onlinelibrary.wiley.com/doi/pdf/10.1046/j.0306-5251.2001.01476.x"}}],"dc:title":[{"@value":"Association between aspirin and upper gastrointestinal complications: Systematic review of epidemiologic studies"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p><jats:bold>Aims </jats:bold> Because of the widespread use of aspirin for prevention of cardiovascular diseases, side‐effects associated with thromboprophylactic doses are of interest. This study summarizes the relative risk (RR) for serious upper gastrointestinal complications (UGIC) associated with aspirin exposure in general and with specific aspirin doses and formulations in particular.</jats:p><jats:p><jats:bold>Methods </jats:bold> After a systematic review, 17 original epidemiologic studies published between 1990 and 2001 were selected according to predefined criteria. Heterogeneity of effects was explored. Pooled estimates were calculated according to different study characteristics and patterns of aspirin use.</jats:p><jats:p><jats:bold>Results </jats:bold> The overall relative risk of UGIC associated with aspirin use was 2.2 (95% confidence interval (CI): 2.1, 2.4) for cohort studies and nested case‐control studies and 3.1 (95% CI: 2.8, 3.3) for non‐nested case‐control studies. Original studies found a dose–response relationship between UGIC and aspirin, although the risk was still elevated for doses lower or up to 300 mg day<jats:sup>−1</jats:sup>. The summary RR was 2.6 (95% CI: 2.3, 2.9) for plain, 5.3 (95% CI: 3.0, 9.2) for buffered, and 2.4 (95% CI: 1.9, 2.9) for enteric‐coated aspirin formulations.</jats:p><jats:p><jats:bold>Conclusions </jats:bold> Aspirin was associated with UGIC even when used at low doses or in buffered or enteric‐coated formulations. The latter findings may be partially explained by channeling of susceptible patients to these formulations.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381981470165781376","@type":"Researcher","foaf:name":[{"@value":"Luis A. Garcı´a Rodrı´guez"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981470165781377","@type":"Researcher","foaf:name":[{"@value":"Francisco J. De Abajo"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"03065251"},{"@type":"EISSN","@value":"13652125"}],"prism:publicationName":[{"@value":"British Journal of Clinical Pharmacology"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2001-11","prism:volume":"52","prism:number":"5","prism:startingPage":"563","prism:endingPage":"571"},"reviewed":"false","dc:rights":["http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.0306-5251.2001.01476.x"},{"@id":"https://bpspubs.onlinelibrary.wiley.com/doi/pdf/10.1046/j.0306-5251.2001.01476.x"}],"createdAt":"2003-03-11","modifiedAt":"2023-10-16","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360002215326624128","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Evidence-based clinical practice guidelines for peptic ulcer disease 2015"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565165279960192","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: the results from the MAGIC study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565165322544384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prospective Cohort Study of Gastrointestinal Complications and Vascular Diseases in Patients Taking Aspirin: Rationale and Design of the MAGIC Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567186751158784","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Interobserver variation in the endoscopic diagnosis of gastroduodenal ulcer scars: implications for clinical management of NSAIDs users"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846640256587776","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Endoscopic and clinical features of gastric ulcers in Japanese patients with or without Helicobacter pylori infection who were using NSAIDs or low-dose aspirin"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204433485568","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Circadian Variations of Gastrointestinal Mucosal Damage Detected with Transnasal Endoscopy in Apparently Healthy Subjects Treated with Low-Dose Aspirin (ASA) for a Short Period"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204776959616","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Study on Risk of Gastrointestinal Complications in Low-dose Aspirin Therapy Using the National Receipt Database"},{"@language":"ja","@value":"ナショナルデータベースを用いた低用量アスピリン療法における消化管傷害リスクに関する研究"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204873666688","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Role of Antithrombotic Therapy and Nonsteroidal Anti-inflammatory Drug Use in Bleeding Gastroduodenal Ulcers"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680157609984","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Prophylactic Effect of Rebamipide on Aspirin-Induced Gastric Lesions and Disruption of Tight Junctional Protein Zonula Occludens-1 Distribution"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1046/j.0306-5251.2001.01476.x"},{"@type":"CROSSREF","@value":"10.1007/s00535-016-1166-4_references_DOI_2cbzgtRda4KyQhQlzzIgGJKGHCM"},{"@type":"CROSSREF","@value":"10.1254/jphs.fp0071422_references_DOI_2cbzgtRda4KyQhQlzzIgGJKGHCM"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.48.1793_references_DOI_2cbzgtRda4KyQhQlzzIgGJKGHCM"},{"@type":"CROSSREF","@value":"10.5649/jjphcs.39.471_references_DOI_2cbzgtRda4KyQhQlzzIgGJKGHCM"},{"@type":"CROSSREF","@value":"10.1007/s00535-013-0839-5_references_DOI_2cbzgtRda4KyQhQlzzIgGJKGHCM"},{"@type":"CROSSREF","@value":"10.1007/s10557-011-6328-2_references_DOI_2cbzgtRda4KyQhQlzzIgGJKGHCM"},{"@type":"CROSSREF","@value":"10.1186/1756-0500-4-409_references_DOI_2cbzgtRda4KyQhQlzzIgGJKGHCM"},{"@type":"CROSSREF","@value":"10.1007/s00535-012-0553-8_references_DOI_2cbzgtRda4KyQhQlzzIgGJKGHCM"},{"@type":"CROSSREF","@value":"10.5551/jat.e615_references_DOI_2cbzgtRda4KyQhQlzzIgGJKGHCM"}]}